Unique ID issued by UMIN | UMIN000016525 |
---|---|
Receipt number | R000018217 |
Scientific Title | Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers |
Date of disclosure of the study information | 2015/02/12 |
Last modified on | 2015/02/12 23:55:49 |
Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers
Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers
Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers
Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers
Japan |
hyperhidrosis
Dermatology |
Others
NO
The purpose of this study is to explore the safety and the effectiveness of rapamycin topical medication for sweating in healthy volunteers.
Safety,Efficacy
Exploratory
Phase I
Skin findings at the site of topical application
Subjective findings at the site of topical application
Serious adverse events
Amount of sweating
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
The bilateral lesions are chosen as the treatment areas.
Rapamycin gel is applied on the left lesion, and the gel base is applied on the right lesion.
Amount of sweating is measured before application, 30 minutes after application, and 60 minutes after application.
20 | years-old | <= |
Not applicable |
Male and Female
1) Healthy volunteers over 20 years of age.
2) Healthy volunteers who can give written consent by themselves in understanding after having received enough explanation on this examination.
1) A person who cannot carry out this treatment plan.
2) A person who have allergy to macrolide antibiotics.
3) A person who received oral administration of rapamycin or RAD001 within 12 months prior to the study entry.
4) A person who received topical administration of rapamycin or RAD001 within three days prior to the study entry.
5) A person who received topical treatment of aluminum chloride or iontophoresis within one months prior to the study entry.
6) A person who received local injection of Botox within three months prior to the study entry.
7) A person who received sympathectomy within 12 months prior to the study entry.
8) A person during pregnancy or lactation
9) A person who cannot undergo QSART and starch-iodine test
10) A person who were judged unsuitable for this study by the investigator.
12
1st name | |
Middle name | |
Last name | Mari Wataya-Kaneda |
Graduate School of Medicine, Osaka University
Department of Dermatology
2-2, Yamadaoka, Suita, Osaka 565-0871, JAPAN
06-6879-3031
mkaneda@derma.med.osaka-u.ac.jp
1st name | |
Middle name | |
Last name | Mari Wataya-Kaneda |
Graduate School of Medicine, Osaka University
Department of Dermatology
2-2, Yamadaoka, Suita, Osaka 565-0871, JAPAN
06-6879-3031
mkaneda@derma.med.osaka-u.ac.jp
Department of Dermatology
Graduate School of Medicine, Osaka University
Ministry of Health, Labour and Welfare
Japan
Ministry of Education, Culture, Sports, Science and Technology of Japan
NO
大阪大学医学部附属病院(大阪府)
2015 | Year | 02 | Month | 12 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 01 | Month | 07 | Day |
2015 | Year | 02 | Month | 12 | Day |
2015 | Year | 02 | Month | 12 | Day |
2015 | Year | 02 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018217